期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study 被引量:4
1
作者 Seamus J Murphy Lesley A Anderson +4 位作者 Brian T Johnston Deirdre A Fitzpatrick Peter RG Watson Pauline Monaghan Liam J Murray 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第46期7290-7295,共6页
AIM: To examine an increased risk of esophageal adenocarcinoma is restricted to patients who develop Barrett's esophagus or whether esophagitis per se is a risk factor for adenocarcinoma.METHODS: A population-base... AIM: To examine an increased risk of esophageal adenocarcinoma is restricted to patients who develop Barrett's esophagus or whether esophagitis per se is a risk factor for adenocarcinoma.METHODS: A population-based cohort of patients with histological evidence of esophagitis without Barrett's esophagus was constructed using electronic pathology reports relating to all esophageal biopsies in Northern Ireland between 1993 and 1996. Person-years of followup and incident cases of esophageal cancer were calculated by linking the cohort to death files and the Northern Ireland Cancer Registry records. Standardized incidence ratios (SIR) were calculated for esophageal cancers (adenocarcinoma, squamous cell carcinoma (SCC), and histologically unspecified cancers).RESULTS: A total of 2 013 patients in the cohort provided 13 559 patient-years of follow-up (mean follow-up 6.7 years). None of the patients developed adenocarcinoma. Three patients developed SCC, and six developed histologically unspecified cancers. The SIR for all esophageal cancers and for SCC were 2.73 (95%CI 1.25-5.19) and 2.93 (95%CI 0.61-8.59), respectively. In a sensitivity analysis in which all unspecified esophageal cancers were treated as adenocarcinomas, the SIR for adenocarcinoma was 2.64 (0.97-5.75).CONCLUSION: The risk of adenocarcinoma is not elevated in patients with histological evidence of esophagitis without Barrett's esophagus; however, these patients may have a moderately increased risk of SCC.Further studies are required to confirm these findings,which suggest that Barrett's esophagus, not esophagitis,is the key precursor lesion in the development of adenocarcinoma. 展开更多
关键词 Barrett's esophagus Esophageal adenocardnoma Esophageal squamous cell carcinoma ESOPHAGITIS Population-based study
下载PDF
胰腺导管腺癌的治疗进展 被引量:4
2
作者 段睿男 钟翔宇 崔云甫 《世界华人消化杂志》 CAS 2016年第8期1206-1212,共7页
胰腺导管腺癌是一种恶性程度极高的消化系恶性肿瘤,约占胰腺癌发病率的90%.其发病隐匿,进展迅速,治疗效果及预后极差,是预后最差的恶性肿瘤之一.外科手术切除,是目前唯一有效的治疗方法,但遗憾的是,很多患者发现时已是晚期,仅有20%-30%... 胰腺导管腺癌是一种恶性程度极高的消化系恶性肿瘤,约占胰腺癌发病率的90%.其发病隐匿,进展迅速,治疗效果及预后极差,是预后最差的恶性肿瘤之一.外科手术切除,是目前唯一有效的治疗方法,但遗憾的是,很多患者发现时已是晚期,仅有20%-30%的患者有手术切除的机会,且手术后的平均存活期仍不足2年.目前针对胰腺癌的各种治疗手段仍不甚理想.对于胰腺导管腺癌的总体治疗策略应是以手术为核心、多学科综合协作下的、个体化治疗模式.近年来胰腺导管腺癌的各种治疗手段成为研究的热点,本文就其根治性手术、姑息性手术、介入治疗、辅助治疗等治疗方案的进展作一综述. 展开更多
关键词 胰腺 胰腺导管腺癌 治疗
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部